Contact
Please use this form to send email to PR contact of this press release:
Generex Subsidiary NGIO Advances COVID-19 Vaccine Program with the Manufacturing of Patent-Pending Ii-Key-SARS-CoV-2 Peptides
TO:
Please use this form to send email to PR contact of this press release:
Generex Subsidiary NGIO Advances COVID-19 Vaccine Program with the Manufacturing of Patent-Pending Ii-Key-SARS-CoV-2 Peptides
TO: